Business CEO appointment

Belén Garijo Appointed Sanofi CEO

Analysis based on 11 articles · First reported Feb 12, 2026 · Last updated Feb 12, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market is likely to react positively to the appointment of Belén Garijo as Sanofi's new CEO, given her strong track record and experience in the pharmaceutical industry. This leadership change is expected to bring renewed focus on strategy execution and R&D innovation, potentially boosting investor confidence in Sanofi's future growth.

Pharmaceuticals Biotechnology

Event Summary

Sanofi's Board of Directors has decided not to renew the Director mandate of Paul Hudson, with his last day as CEO set for February 17, 2026. Following this, Belén Garijo has been appointed as the new Chief Executive Officer, effective April 29, 2026, after the Annual General Meeting. Olivier Charmeil will serve as Interim CEO during the transition. Belén Garijo, previously CEO of Merck Group and a former Sanofi executive, is expected to enhance the implementation of Sanofi's strategy, focusing on productivity, governance, and R&D innovation. Her extensive experience and leadership in the pharmaceutical industry are highlighted as key assets for Sanofi's future growth.

Key Actions

100 Sanofi appointed new Chief Executive Officer Belén Garijo

100 Belén Garijo joined as Chief Executive Officer Sanofi

80 Sanofi did not renew Director mandate Paul Hudson

30 Sanofi appointed Interim Chief Executive Officer Olivier Charmeil

15 Belén Garijo left Chief Executive Officer position Merck Group

Entities Involved

stock

Sanofi

Sanofi's Board of Directors appointed Belén Garijo as the new Chief Executive Officer, replacing Paul Hudson. This leadership change is expected to bring increased rigor to strategy implementation and accelerate future preparations, focusing on productivity, governance, and R&D innovation.

Importance 100 Sentiment 25

per

Belén Garijo

Belén Garijo has been appointed as the new CEO of Sanofi. Her appointment is viewed positively due to her extensive experience in the pharmaceutical industry, including her previous role as CEO of Merck Group and 15 years at Sanofi.

Importance 95 Sentiment 40

per

Paul Hudson

Paul Hudson's mandate as Director and Chief Executive Officer of Sanofi will not be renewed. The Board thanked him for his contributions over the past six years.

Importance 70 Sentiment -10

per

Olivier Charmeil

Olivier Charmeil will serve as Interim Chief Executive Officer of Sanofi during the transition period between Paul Hudson's departure and Belén Garijo's official start.

Importance 30 Sentiment 0

per

Frédéric Oudéa

Frédéric Oudéa, Chairman of Sanofi's Board of Directors, expressed confidence in Belén Garijo's ability to lead the company's next growth cycle.

Importance 20 Sentiment 0

stock

Merck Group

Belén Garijo previously served as the Chief Executive Officer of Merck Group, where she was the first woman to lead a DAX40 company in Germany.

Importance 15 Sentiment 0

stock

Banco Bilbao Vizcaya Argentaria

Belén Garijo is a member of the Board of Directors of Banco Bilbao Vizcaya Argentaria, highlighting her strategic leadership experience beyond the pharmaceutical industry.

Importance 5 Sentiment 0

+ 3 more entities View on Dashboard

Relationships

Belén Garijo related ↔ Sanofi

Paul Hudson related ↔ Sanofi

Olivier Charmeil related ↔ Sanofi

Belén Garijo related ↔ Merck Group

Belén Garijo related ↔ Banco Bilbao Vizcaya Argentaria

Belén Garijo related ↔ L Oréal

Frédéric Oudéa related ↔ Sanofi

Belén Garijo related ↔ Paul Hudson

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard